COVID-19 has been a nightmare for most for-profit health care operators according to HBI's online survey of 100 operators internationally. That is reflected in the response which also shows the great switch to digital health.
Making sense of the money markets isn't easy right now. But some big players - Ramsay, Zur Rose and TPG are still raising money and some sectors such as German outpatient are still seeing M&A consolidation.
The post-COVID-19 financial outlook for private hospitals in Western Europe is becoming clearer. Those in statutory insurance-funded markets are likely to be protected by the public payor while private insurers look unlikely to shoulder the burden. And reimbursement for any COVID-19 care will barely make up the difference.
The UAE's decision to mass-test its population for COVID-19 and develop responses at the federal rather than emirate-level look to be paying dividends, notwithstanding its very young population. But how far is the private sector involved in the response, both in the UAE and neighbouring Saudi Arabia? HBI talks to local hospital, lab and advisory sources.
Patient footfall for outpatient care across the world has all but stopped. Exclusive data from DocPlanner shows which specialities have seen the biggest drop in appointments booked and where telemedicine is really picking up some of the slack. We assess this against outpatient volumes in Singapore during SARS to see when it might pick up.
Nationwide lockdowns and travel restrictions are hitting private hospital chains in India, Turkey and Southeast Asia, where the biggest groups garner 10-15% of revenues from international patients. HBI talks to an India-based source to find out more and looks at how operators are faring.
Labs across Europe are set to lose at best a third and at worst all of their routine testing volumes as healthcare systems narrow their focus on coronavirus and patients stay away. The picture is even bleaker for imaging groups.
Listed hospital and outpatient service operators across the globe have adjusted 2020 guidance, issued profit warnings and cancelled dividends as elective and private activity plummets due to the COVID-19 outbreak. Operators more focused on publicly-funded work seem to be doing slightly better.
Public elective surgeries are being cancelled across Europe, replaced in part by additional for-profit outsourcing, and governments are buying private hospital capacity for an expected flood of COVID-19 cases. In some countries, the stop on electives is across both public and private sectors. HBI investigates.
In the second of our two-part deep dive into how COVID-19 is hitting healthcare markets across EMEA, we ask how hospitals are coping with spiralling staff sickness and a flood of patients, and whether the care and dialysis sectors can stay afloat given the risk the virus poses to their most vulnerable patients.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.